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IntroductIon
Innate lymphoid cells (ILCs) are a growing family of innate 
lymphocytes with diverse phenotypic and functional prop-
erties (Spits et al., 2013). They have a critical role in various 
processes, such as the development of lymphoid structures, 
the generation and maintenance of immune homeostasis es-
pecially at mucosal sites, tissue remodeling, and the mainte-
nance of epithelial integrity (Finke et al., 2002; Fukuyama 
et al., 2002; Monticelli et al., 2011; Mchedlidze et al., 2013; 
Goto et al., 2014). However, they have also been implicated 
in the control and suppression of solid tumors (Eisenring et 
al., 2010; Ikutani et al., 2012; Kirchberger et al., 2013; Bie et 
al., 2014; Chan et al., 2014; Carrega et al., 2015; Crome et al., 
2017; Irshad et al., 2017).
Group 1 ILCs include NK cells and other non-NK 
ILC1 cells, all expressing the transcription factor T-bet and 
secreting IFN-γ when stimulated with IL-12, IL-15, or IL-18 
(Fuchs and Colonna, 2013; Klose et al., 2014). Despite their 
similarities to NK cells in transcription factor profiles and 
cytokine expression, the role of ILC1s in tumor surveillance 
remains to be established. ILC2s produce type 2 cytokines, 
such as IL-5 and IL-13, and have been implicated in both 
tumor surveillance and tumorigenesis. Thus, whereas induc-
tion of IL-13 by IL-33 in ILC2s promotes tumor growth 
in two distinct mouse models (Jovanovic et al., 2014; Li et 
al., 2014), anti-tumor activity against lung metastasis requires 
IL-5 production by ILC2s (Ikutani et al., 2012).
Genetic fate mapping identifies type 3 ILCs by the ex-
pression of retinoic acid-receptor-related orphan receptor 
(ROR)γt during their emergence (Eberl and Littman, 2004). 
These ILC3s include C-C chemokine receptor (CCR)6+ 
ILC3s (mainly representing lymphoid tissue inducer cells 
[LTi’s]), CCR6− natural cytotoxicity receptor (NCR)+ ILC3s, 
and CCR6−NCR− ILC3s (Klose et al., 2013). ILC3s have 
also been reported to have pro- or antitumorigenic effects 
in different experimental setups. They were shown to pro-
mote bacteria-induced colon cancers in an IL-22–dependent 
manner, and IL-23 stimulation induces de novo development 
of intestinal adenomas (Kirchberger et al., 2013; Chan et al., 
2014). In contrast, type 3 ILCs have been implicated in tumor 
suppression in a model of malignant melanoma (Eisenring et 
al., 2010). In that particular study, IL-12 was responsible for 
the tumor-suppressive capacity of Rorcfm+ ILCs (Eisenring 
et al., 2010). The tumor-suppressive cytokine IL-12 was pre-
viously described to promote T-bet expression resulting in 
the loss of RORγt-inducing so-called “ex-ILC3s,” which are 
phenotypically similar to ILC1s (Vonarbourg et al., 2010). In 
addition, IL-12 induces a reversible differentiation of human 
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Figure 1. ILcs reside in various tissues and rorcfm+ ILcs from spleen and small intestine cluster in demarcated cluster sets. (A) Flow cytometric 
analysis to identify Rorcfm+ ILCs in various organs of Rorcfm-Rag1−/− mice, including lymphoid organs, such as skin-draining LNs (sdLN), mesenteric LNs 
(mLN), spleen (spl), and thymus as well as nonlymphoid organs, such as the liver, lung, siLP, and skin in a steady state. Representative graphs of two inde-
pendent experiments, n ≥ 4 each. (B) Total counts of Rorcfm+ ILCs within the CD45 compartment of various organs of Rorcfm-Rag1−/− mice (skin represents 
total counts of two ears). Graphs represent pooled data from two independent experiments, n ≥ 4 each (means ± SEM). (C) Histogram overlay of splenic 
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intestinal ILC3s and ILC2 cells into type 1–like ILCs under 
inflammatory conditions (Bernink et al., 2015; Bal et al., 
2016; Lim et al., 2016; Ohne et al., 2016; Silver et al., 2016). 
Besides the nonredundant role of this cytokine in the plas-
ticity of ILC subsets, little is known about the role of the 
tissue microenvironment in delineating phenotypic and func-
tional ILC fate. Therefore, whether the functional ILC fate is 
shaped not only during its lineage commitment but also by 
the tissue microenvironment is currently unclear.
By systematically interrogating one functional prop-
erty of tissue-resident ILCs, namely IL-12–mediated tu-
mor-suppressive capacity, we observed that the specific tissue 
microenvironment determines the fate and function of dis-
tinct Rorcfm+ ILCs subtypes. Intestinal Rorcfm+ ILCs predom-
inantly retained expression of RORγt, whereas progeny of the 
same precursor migrating into lymphoid tissues up-regulated 
T-bet and acquired potent tumor-suppressive properties. We 
thus propose that the individual tissue microenvironment 
shapes the functional specialization of ILCs. Of note, con-
ventional NK cells and bona fide ILC1s, despite being highly 
responsive to IL-12, did not have tumor-suppressive activity, 
suggesting that tissue microenvironment-induced plasticity 
combined with ontogeny and early transcriptional imprint-
ing determines ILC function.
resuLts
rorcfm+ ILcs reside in various tissues and adapt to 
the local microenvironment
ILC3s express the transcription factor RORγt and regu-
late various immune responses, most prominently within 
the intestinal tract (Sanos et al., 2009; Mortha et al., 2014; 
Bernink et al., 2015; Hepworth et al., 2015). Other than 
barrier-tissue immunity and their role in lymphoid organ-
ogenesis, little is known about the prevalence and function 
of RORγt-dependent ILCs. Therefore, we characterized 
the progeny of RORγt-dependent ILC precursors in vari-
ous lymphoid and nonlymphoid tissues in steady state with 
multiparametric flow-cytometry analysis (Fig.  1  A). We 
took advantage of genetic fate mapping using Rorc-CreTg; 
Rosa26ReYFP/+ mice (from now an referred to as Rorcfm 
mice; Eberl and Littman, 2004), in which all cells that ex-
pressed RORγt at any time during their development, as 
well as in their progeny, are permanently marked with YFP 
(hereafter, called Rorcfm+ cells). By crossing Rorcfm mice 
onto a Rag1−/− background, we eliminated all canonical 
fate-mapped cells (i.e., T lymphocytes) and exclusively la-
beled TCR-negative Rorcfm+ ILC. The frequencies and total 
cell numbers of Rorcfm+ ILCs in steady state were expectedly 
highest in the small intestine (Fig. 1, A and B; and Fig. S1, A 
and B). However, we found significant numbers of Rorcfm+ 
ILCs in the thymus and secondary lymphoid organs as well, 
including skin-draining LNs, mesenteric LNs, and spleen, and 
in nonlymphoid organs, such as liver, lung, and skin.
To further characterize Rorcfm+ ILCs of distinct tissues, 
we performed phenotypic profiling with ILC and NK cell 
markers, revealing vast differences in Rorcfm+ ILCs of various 
organs, in particular, between lymphoid and nonlymphoid 
tissues (Fig. S1 C). We chose a representative lymphoid tis-
sue (i.e., spleen) and nonlymphoid tissue (i.e., small intestinal 
lamina propria [siLP]) for further detailed analysis (Fig. 1 C). 
Lymphoid tissue–resident Rorcfm+ ILCs express high levels 
of NK cell–associated markers, such as NKp46, NK1.1, and 
CD49b and, thus, phenotypically resemble NK cells, even 
though they clearly arise from a distinct lineage (as defined by 
Rorcfm). In contrast, intestinal Rorcfm+ ILCs homogenously 
express IL-7Rα and Thy1.2, heterogeneously express NKp46, 
but are mostly negative for NK1.1 and CD49b (Fig. 1 C).
Numerous lineage-defining markers for the different 
ILC subsets have been proposed, with some degree of un-
certainty as to whether each subset represents a stable lineage 
(Spits et al., 2013). Given the apparent heterogeneity and/
or plasticity, we decided to use a computer-aided cluster-
ing approach for the unsupervised identification of distinct 
fates and phenotypes of RORγt-dependent ILCs. Therefore, 
CD45+Rorcfm+ ILCs of spleen and siLP—without any fur-
ther pregating—were fed into the dimensionality reduction 
algorithm t-stochastic neighbor embedding (t-SNE), fol-
lowed by analysis of the combined data sets with flowSOM 
(k = 5). Strikingly, the unsupervised clustering separated 
splenic and siLP Rorcfm+ ILCs into clearly demarcated clus-
ter sets (Fig.  1  D). Although almost all siLP Rorcfm+ ILCs 
grouped together in one separate cluster (cluster 4), splenic 
ILCs were split into 4 clusters (cluster 1–3 and 5), indicat-
ing greater diversity among splenic subsets of type 3 ILCs 
compared with siLP ILC3s.
As shown previously (Fig.  1 C), siLPs (represented in 
cluster 4) express mainly ILC3-associated markers (Fig. 1, E 
and F). The splenic ILC clusters could be matched to previ-
ously described ILC3 subsets. Cluster 1 represents so-called 
CCR6−NCR+ ILC3s (Klose et al., 2013), whereas cluster 3 
resembles CCR6+ ILCs (Klose et al., 2013). Because of the 
high expression of NK cell markers and the low expression of 
ILC3-associated markers, cluster 2 may represent “ex-ILC3s,” 
whereas cells of cluster 5 may hold LTi-like cells express-
(spl) Rorcfm+ ILCs (black continuous line), siLP Rorcfm+ ILCs (gray continuous line), and splenic (spl) Rorcfm- NK cells (dotted line). Representative histograms 
of four independent experiments, n ≥ 5 each. (D) Dimensionality reduction using t-SNE. Data from 4 × 104 Rorcfm+ ILCs of spleen and siLP (gated on live, 
single CD45+Rorcfm+ ILCs) were transformed and plotted in two t-SNE dimensions using R software. Clustering was performed using the flowSOM algorithm 
(k = 5). Depicted are the combined spleen and siLP data sets (left), the siLP data set only (middle), and the spleen data set only (right). (E) ILC3-associated 
and NK cell–associated markers plotted in a heat map across flowSOM clusters from D. (F) Expression pattern of ILC3-associated and NK cell–associated 
markers depicted in the two t-SNE dimensions.
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Figure 2. the tissue microenvironment dictates the fate of rorcfm+ ILcs. (A) Schematic representation of the experimental setup. Rorcfm+ ILCs from 
spleen (spl) or siLP of Rorcfm-Rag1−/− mice were isolated using flow cytometric cell sorting and adoptively transferred into lymphopenic Rag2−/−Il2rg−/− mice. 
After 5 wk, various organs were analyzed. (B) Distribution of adoptively transferred Rorcfm+ ILCs of splenic (spl, top) and siLP (bottom) origin, homing to 
various organs (clockwise: liver, blood, spleen, siLP, or lung) within Rag2−/−Il2rg−/− mice. Graphs represent pooled data from three independent experiments, 
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ing IL-7Rα, low levels of c-Kit, Sca-1, and CCR6 (com-
pare CCR6 expression map of Fig.  1  F), but no NK cell 
markers. Of note, similar splenic Rorcfm+ ILCs clusters were 
found regardless of whether they were analyzed in WT or 
Rag-deficient mice (Fig. S1, D–F). These data reveal the 
distinct characteristics of splenic Rorcfm+ ILCs and siLP 
Rorcfm+ ILCs, despite sharing the same lineage, and suggest 
a phenotypic specialization of Rorcfm+ ILCs driven by the 
tissue microenvironment.
the tissue microenvironment determines 
the fate of type 3 ILcs
Whether the phenotypic specialization of Rorcfm+ ILCs from 
various organs is stable over time or whether these pheno-
types are plastic and imprinted by the local tissue micro-
environment is a matter of speculation. To interrogate the 
plasticity of type 3 ILCs, we adoptively transferred Rorcfm+ 
ILCs isolated from various organs into Rag2−/−Il2rg−/− mice, 
allowing tissue homing akin to the homeostatic expansion 
of T lymphocytes in a lymphopenic environment (Fig. 2 A). 
Regardless of the tissue from which the Rorcfm+ ILCs were 
isolated, they stochastically homed to various organs. Rorcfm+ 
ILCs isolated, for example, from the spleen did not “home” 
specifically into the spleen but were similarly disseminated 
across all examined organs. Conversely, Rorcfm+ ILCs iso-
lated from the small intestine, likewise, colonized lymphoid 
and nonlymphoid organs, without the predisposition to 
home into the gut (Fig.  2 B). Importantly, the phenotypic 
properties and expression of lineage markers of adoptively 
transferred Rorcfm+ ILCs depended on the local tissue envi-
ronment they encountered and not on their origin (Fig. 2 C). 
In other words, Rorcfm+ ILCs colonizing the spleen expressed 
NK cell-associated markers (Fig. 2 C); Rorcfm+ ILCs colo-
nizing the small intestine adopted the phenotype of ILC3s 
by expressing, for example, Thy1.2 but no NK cell-associated 
markers (Fig. 2 C). To investigate whether this phenomenon 
was caused by selective migration (and/or survival) of a sta-
ble subpopulation or was indeed stochastic, we sorted NCR+ 
ILC1-like (NKp46+NK1.1+Rorcfm+ ILCs) or NCR−ILC3s 
(NKp46−NK1.1−Rorcfm+ ILCs) cells and adoptively trans-
ferred them into Rag2−/−Il2rg−/− mice. As with unfraction-
ated Rorcfm+ ILCs, we found no clear homing preferences of 
the purified subsets but observed a distribution across various 
organs (Fig.  2  D). Moreover, both subpopulations changed 
their phenotypes according to the organs they encountered, 
thus favoring the notion of site-specific, plastic behavior over 
selective migration or survival of a specific ILC subset.
Taken together, these results reveal that the tissue mi-
croenvironment in the steady state provides strong guidance 
cues for the phenotypic adaptation of ILCs to the individ-
ual tissue. This raises the question of whether the phenotypic 
changes driven by the tissue microenvironment also translate 
into functional differences regarding cytokine responsive-
ness and tumor protection.
the tissue microenvironment dictates the 
function of rorcfm+ ILcs
To evaluate functional differences of Rorcfm+ ILCs originat-
ing from either a lymphoid or nonlymphoid environment, we 
investigated the capacity of these cells to modulate melanoma 
growth in the context of the tumor-suppressive cytokine 
IL-12. We engineered B16.F10 melanoma cells to constitu-
tively express a recombinant IL-12:Fc fusion protein or an 
Fc-tag alone (hereafter, called B16-IL-12 vs. B16-ctrl; Eisen-
ring et al., 2010; vom Berg et al., 2013) and cotransplanted 
these cells with Rorcfm+ ILCs s.c. into Il12rb2−/− mice. In this 
particular setting, Rorcfm+ ILCs comprise the only IL-12–re-
sponsive cell type in the tumor (Fig. 3 A). Small numbers of 
lymphoid tissue-derived Rorcfm+ ILCs were able to suppress 
tumor growth over an extended period (Fig. 3 B). In contrast, 
Rorcfm+ ILCs originating from the siLP failed to reject tumors, 
suggesting that their conditioning in the gut microenviron-
ment stunted their tumor-suppressive capacity. Conventional 
NK cells also failed to reject B16–IL-12 melanomas, despite 
their phenotypic similarity to splenic Rorcfm+ ILCs (Fig. 3, 
B and C). Tumor suppression by splenic ILC3s resulted in 
extended survival (Fig. 3 D). Of note, LN-derived Rorcfm+ 
ILCs possessed tumor-suppressive capacity, whereas hepatic 
Rorcfm+ ILCs, similar to siLP Rorcfm+ ILCs, did not induce 
tumor suppression (Fig. S2, A and B). To assess whether our 
observations resulted from the lymphopenic environment in 
Rag−/− mice, we confirmed our findings using Rorcfm+ ILCs 
from WT mice: splenic Rorcfm+ ILCs retain tumor-suppressive 
properties, whereas neither siLP Rorcfm+ ILCs nor phenotyp-
ically similar Rorcfm− NK cells inhibit tumor growth (not 
depicted). Our data suggest both phenotypic and functional 
specialization of tissue-resident Rorcfm+ ILCs. Thus, the func-
tion of ILCs is shaped not only during their lineage commit-
ment but also by the tissue microenvironment.
tumor-suppressive rorcfm+ ILcs down-regulate rorγt and 
increase t-bet expression
Previously, IL-23 receptor expression was reported on ILC3s, 
whereas IL-12 receptor expression was restricted to ILC1s 
n ≥ 3 each. (C) Flow cytometric analysis of live, single, CD45+Rorcfm+ ILCs originating from spleen (spl, top) or siLP (bottom) after 5 wk of expansion in 
Rag2−/−Il2rg−/− mice. Graphs represent pooled data from three independent experiments, n ≥ 3 each. (D) Distribution of adoptively transferred highly 
purified splenic NCR+ (NKp46+NK1.1+) Rorcfm+ ILCs (top) and NCR− (NKp46−NK1.1−) siLP Rorcfm+ ILCs (bottom), homing to various organs (clockwise: liver, 
blood, spleen, siLP, or lung) within Rag2−/−Il2rg−/− mice. Graphs represent pooled data from two to five independent experiments, n ≥ 5. (D) Flow cytometric 
analysis of spleen-derived NCR+Rorcfm+ ILCs (top) or siLP-derived NCR−Rorcfm+ ILCs (bottom) after 5 wk of expansion in Rag2−/−Il2rg−/− mice (gated on live, 
single, CD45+ Rorcfm+ ILCs). Representative histograms from two to five independent experiments, n ≥ 5.
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(Vonarbourg et al., 2010). To determine whether the tissue 
influences, which render the tumor-suppressive function of 
Rorcfm+ ILCs also alter their responsiveness toward IL-12/
IL-23, we quantified the expression of IL-12/IL-23 recep-
tors on isolated Rorcfm+ ILCs from spleen and siLP. Splenic 
Rorcfm+ ILCs expressed higher levels of the IL-12–specific 
receptor subunit Il12rβ2 compared with siLP Rorcfm+ ILCs, 
which expressed the IL23r (Fig. 4 A). Thus, the heightened 
sensitivity of splenic Rorcfm+ ILCs to IL-12 may explain their 
tumor-suppressive capacity.
A previous study suggested an inverse correlation be-
tween IL-12 receptor and RORγt expression in Rorcfm+ 
ILCs (Vonarbourg et al., 2010). To evaluate whether the tis-
sue microenvironment directly influences RORγt expres-
sion, we took advantage of the Rorcfm (Rorcfm+ ILCs) and 
Rorc-reporter (Rorcrep+ ILCs) mice and compared their 
ILC3 compartment of spleen and siLP. Although the small 
intestine was rich in both Rorcfm+ and Rorcrep+ ILCs, most 
splenic Rorcfm+ ILCs lost RORγt expression (Fig. 4 B). Ac-
cordingly, most splenic ILC3s expressed T-bet uniformly and 
the cytokines IFN-γ, GM-CSF (Fig.  4, C–E), granzyme, 
and perforin (not depicted), thus corroborating a shift of tu-
mor-suppressive Rorcfm+ ILCs toward type 1 immunity.
IL-12 activates the tumor microenvironment and the 
recruitment of tumor-invading ILcs
To assess the effect of IL-12 on the tumor microenvi-
ronment and how that influences ILC-driven immune 
responses, we injected B16-control or B16–IL-12  s.c. 
into C57BL/6 or IL-12-unresponsive Il12rb2−/− mice 
(Fig.  5  A). On day 5 after transplantation, the complete 
tumor tissue was resected, and total mRNA was analyzed 
by next-generation sequencing (NGS). Fig.  5  B depicts 
the signature of the tumor microenvironment in the pres-
ence or absence of IL-12. Increased expression of both 
IL-12 subunits, STAT4 and IFN-γ, confirmed the IL-12 
responsiveness of the tumor microenvironment at early 
times (not depicted). IL-12 expression induced a signa-
Figure 3. splenic rorcfm+ ILcs suppress tumor growth in an IL-12–dependent manner. (A) Schematic representation of the experimental setup. 
B16–IL-12 tumor cells were s.c. injected into Il12rb2−/− mice with or without Rorcfm+ ILCs, isolated from various organs of Rorcfm-Rag1−/− mice using flow 
cytometric cell sorting. (B) Tumor growth of B16–IL-12 tumor cells coinjected with splenic (spl) Rorcfm+ ILCs (open circles), siLP Rorcfm+ ILCs (open squares), 
or splenic (spl) Rorcfm-NK cells (closed squares), respectively, or in the absence of ILCs (closed circles) over time. For comparison of the tumor growth curve 
two-way ANO VA with Tukey’s multiple comparisons test was used. ***, P < 0.001. (C) Quantification of tumor growth at d 24 after tumor inoculation. 
One-way ANO VA with Tukey’s multiple comparisons test was performed. ***, P < 0.001. (D) Kaplan-Meier survival curve of mice coinjected with B16–IL-12 
and splenic (spl) Rorcfm+ ILCs (bold continuous line), siLP Rorcfm+ ILCs (gray continuous line), splenic (spl) Rorcfm- NK cells (gray dashed line), or in the absence 
of ILCs (bold dotted line). (B–D). Graphs represent pooled data from three independent experiments, n ≥ 4 each (means ± SEM). For comparison of survival 
curves, a Lox-rank (Mantel-Cox) test was used. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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ture in the tumor microenvironment reminiscent of type 
1 immune responses, as shown by strong up-regulation of 
IFN-γ, the FAS ligand, and the type 1–associated chemo-
kine receptors C-X-C chemokine receptor (CXCR)6, 
CCR5, CXCR3, and CCR1 (Fig. 5 C). Additionally, sev-
eral chemokines, such as C-C chemokine ligand (CCL)2, 
CCL4, CCL7, CCL8, and CCL12, known to attract/re-
cruit lymphocytes, monocytes, and a variety of other im-
mune cells were up-regulated in the presence of IL-12 
(Fig. 5 D). Taken together, the pro-inflammatory responses 
induced by IL-12 may support the invasion and activation 
of ILCs into the tumor tissue.
We next investigated whether the effect of IL-12 on the 
tumor microenvironment would indeed favor the recruitment 
of tumor-suppressive Rorcfm+ ILCs. We found significantly el-
evated frequencies of Rorcfm+ ILCs in IL-12–treated tumors 
Figure 4. splenic rorcfm+ ILcs acquire an “ex-ILc3” phenotype. (A) Normalized expression of Il12rb2 and Il23r mRNA levels of flow cytometric–sorted 
splenic and siLP Rorcfm+ ILCs. Graphs represent pooled data from three independent experiments, n = 3 each (means ± SEM). Two-tailed unpaired t test was 
performed. *, P < 0.05. (B, left) Schematic representation of Rorcfm-Rag1−/− and reporter RorcGFP-Rag1−/− mice. (Right) Flow cytometric analysis of splenic 
and siLP ILCs in reporter (left; GFP) and fm (right; YFP) mice. Representative graphs of three independent experiments, n ≥ 4 each. (C) Histogram overlay of 
transcription factors expressed by splenic (spl) Rorcfm+ ILCs (bold continuous line), siLP Rorcfm+ ILCs (gray continuous line), or splenic (spl) Rorcfm- NK cells 
(dotted line). Representative histograms of three independent experiments, n = 4 each. (D) Quantification of RORγt- or T-bet–expressing splenic (spl) or 
siLP Rorcfm+ ILCs. Graphs represent pooled data from three independent experiments, n = 4 each (means ± SEM). Two-tailed, unpaired t test was performed. 
*, P < 0.05; ***, P < 0.001. (E, left) Flow cytometric analysis of cytokine expression by splenic (spl) or siLP Rorcfm+ ILCs. Representative histograms of three in-
dependent experiments, n = 4 each. (Right) Quantification of cytokine expressing splenic (spl) or siLP Rorcfm+ ILCs. Graphs represent pooled data from three 
independent experiments, n ≥ 3 each (means ± SEM). One-way ANO VA with Tukey’s multiple comparisons test was performed. *, P < 0.05; ***, P < 0.001.
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Figure 5. IL-12 alters the tumor microenvironment and increases the frequency of tumor-infiltrating rorcfm+ ILcs. (A) Schematic represen-
tation of the three experimental groups used for NGS: B16-control (ctrl) tumor cells were injected into WT mice and B16-IL-12 tumor cells into WT or 
Il12rb2−/− mice, respectively. NGS was performed on RNA obtained from tumors 5 d after tumor inoculation. (B) Heat map of differentially expressed genes 
in the tumor tissue. (C) Heat map of expression levels of Th1- and Th2-associated genes of B16–IL-12 in WT mice (means of three tumors depicted). (D) 
Normalized counts of the chemokines Ccl2, Ccl4, Ccl7, Ccl8, and Ccl12. Each data point represents one tumor (means ± SEM). One-way ANO VA with Tukey’s 
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compared with controls (Fig. 5, E and F). Similar to lymphoid 
tissue–resident Rorcfm+ ILCs, tumor-infiltrating Rorcfm+ 
ILCs mostly expressed Thy1.2, but also the markers NKp46, 
NK1.1, and CD49b, classifying them as phenotypically sim-
ilar to NK cells (Fig. 5 G). Our data show that the presence 
of IL-12 supports the recruitment of ILCs, which resemble 
tumor-suppressive, lymphoid tissue–resident Rorcfm+ ILCs.
ILc1s resemble tumor-suppressive rorcfm+ ILcs but fail 
to suppress tumor growth
Previous studies demonstrated the plastic nature of ILCs, in 
particular the conversion of ILC3 toward type 1 ILC polar-
ization (Vonarbourg et al., 2010; Klose et al., 2013, 2014; Ber-
nink et al., 2015). Because we found that tumor-suppressive 
Rorcfm+ ILCs acquire a phenotype similar to type I ILCs (los-
ing RORγt and expressing NCRs), we evaluated the capac-
ity of the phenotypically similar Eomes− ILC1s to suppress 
tumor growth in an IL-12–dependent manner.
We made use of a recently introduced mouse model, 
combining the fm of Rorc with the reporter for Eomes 
(EomesGFP+; Klose et al., 2014), allowing for the identifi-
cation of conventional NK cells (Rorcfm-Eomes+), ILC1s 
(Rorcfm−Eomes−) and ILC3s (Rorcfm+) by their transcrip-
tion profile and ontogeny tracing (Fig.  6 A and Fig. S3, A 
and B). When characterizing the splenic ILC compartment, 
Eomes+ NK cells clearly dominate in numbers, comprising 
∼50% of all CD45+lin−cells and almost 80% of the splenic 
ILC1 and ILC3 compartment (Fig. 6 B), in comparison to 
Eomes− ILC1s or Rorcfm+ ILCs, which represent 18% or 4%, 
respectively, of the ILC compartment (Fig.  6  B). As previ-
ously observed (Klose et al., 2014), Eomes− ILC1s showed 
a heterogeneous expression pattern of Thy1.2 and IL-7Rα 
(Fig.  6  C), expressed T-bet and were negative for RORγt 
and Eomes, as confirmed by intracellular staining (not de-
picted). Thus, Eomes− ILC1s clearly show a type 1 phenotype 
resembling that of most lymphoid tissue-resident Rorcfm+ 
ILCs, raising the question as to whether they also have tu-
mor-suppressive properties.
We challenged Il12rb2−/− mice with B16–IL-12 tumor 
cells infused with one of the respective splenic ILC subsets 
(for schematic representation of the experimental setup, see 
Fig. 3 A). Despite the phenotypic similarities and the same 
tissue origin as Rorcfm+ ILCs, Eomes− ILC1s failed to sup-
press tumor growth (Fig. 6, D and E), pointing out an essen-
tial role of the ontogeny for defining their function. Taken 
together, the type 1 phenotype in lymphoid tissues applies to 
Eomes− ILC1s, conventional Eomes+ NK cells and Rorcfm+ 
ILCs, of which only the latter ones are tumor-suppressive in 
response to the proinflammatory cytokine IL-12.
To further explore the differences between tumor- 
suppressive and nonsuppressive ILCs, we performed tran-
scriptome analysis of splenic Rorcfm+ ILCs, Eomes− ILC1s 
and Eomes+ NK cells, as well as siLP Rorcfm+ ILCs. Compel-
lingly, principle component analysis (PCA) shows similarity 
between splenic Rorcfm+ ILCs and Eomes− ILC1s. Compo-
nent 3 separates splenic Rorcfm+ ILC3s from the other ILC 
subsets, indicating that differentially expressed genes in this 
population may be involved in their functional differences in 
tumor suppression (Fig. 6 F). Basic hierarchical clustering of 
the four populations showed that splenic and siLP Rorcfm+ 
ILCs were more closely related to each other compared 
with the type 1 ILCs, despite them being isolated from two 
distinct organs, reflecting the strong guidance cues of their 
common cellular derivation (Fig. 6 G and Fig. S4, A–D). Fur-
ther in-depth analysis revealed that wide ranges of cellular 
mechanisms are significantly altered in tumor-suppressive 
splenic Rorcfm+ ILCs compared with all the other analyzed 
ILC subsets. Differences in leukocyte cell–cell adhesion and 
leukocyte-activation pathways, including the greater expres-
sion of genes such as Ccr7, Cxcr5, Cd4, Cd81, and Erbb2 
hints toward a distinct migration and homing mechanisms of 
splenic Rorcfm+ ILCs in response to malignancies. Similarly, 
genes involved in the cytokine-mediated signaling pathways 
and cellular proliferation (Krt8, Tnfrsf11a [encoding RANK, 
i.e., TRA NCE], and Adm, Cd81, Erbb2, Wisp2, or Mar-
veld3) are altered, pointing toward distinct functionality of 
splenic Rorcfm+ ILCs. Similar to previously published stud-
ies, genes involved in the pathway of LN development were 
differentially expressed in splenic Rorcfm+ ILCs, confirming 
the validity of the approach (Fig. S4 E). Taken together, tu-
mor-suppressive splenic Rorcfm+ ILCs possess transcriptional 
differences compared with nonsuppressive siLP Rorcfm+ ILCs 
or other splenic type 1 ILCs, which may explain their dif-
ferential functionality. Thus, the classification of ILC subsets 
based on their superficial phenotypic appearance, that is, sur-
face markers alone, seems arbitrary in light of their function 
and signature being guided primarily by their ontogeny (i.e., 
transcriptional regulation) and the tissue they reside in.
splenic rorcfm+ ILcs change the tumor microenvironment, 
favoring leukocyte invasion
The mechanism by which IL-12–activated Rorcfm+ ILCs 
suppress tumor growth remains unknown. The fact that 
Rorcfm+ ILCs only express low amounts of cytotoxic mol-
multiple comparisons test was performed. *, P < 0.05; **, P < 0.01; ***, P < 0.001. (E) Flow cytometric analysis of live, single CD45+ Rorcfm+ ILCs in the tumor 
tissue (growing in Rorcfm-Rag1−/− mice) 5 d after tumor inoculation. (F) Frequencies of tumor-infiltrating Rorcfm+ ILCs within the CD45 compartment 5 d 
after tumor inoculation in the presence or absence of intratumorally administered IL-12. Representative graph of one of three independent experiments, 
n ≥ 3 each (means ± SEM). Two-tailed, unpaired t test was used. *, P < 0.05. (G) Histogram overlay of Rorcfm+ ILCs of tumor (dotted line), spleen (spl, bold 
continuous line), and siLP (gray continuous line) 5 d after tumor inoculation into Rorcfm-Rag1−/− mice. Representative histograms from three independent 
experiments, n = 5 each.
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Figure 6. ILc1s phenotypically resemble tumor-suppressive rorcfm+ ILcs but fail to inhibit tumor growth. (A) Schematic representation of the 
Rorccre mice crossed to the EomesGFP-Rosa26ReYFP/+ mice labeling all cells expressing RORγt with enhance YFP and all cells expressing Eomes with GFP. 
(B, left) Quantification of the different ILC subsets within the CD45+ compartment of the spleen. (Right) Distribution of NK cells (dark bar), ILC1s (light 
bar), and ILC3s (white bar) within the ILC compartment of the spleen. Graphs represent pooled data from two independent experiments, n ≥ 5 each 
(means ± SEM). (C) Histogram overlay of different ILC subsets in the spleen. Representative histograms of two independent experiments, n ≥ 5 each. 
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ecules, compared with NK cells or ILC1s (Fig. S5 A), and 
suppression of B16–IL-12 tumors is perforin independent 
(Eisenring et al., 2010) led us to hypothesize that Rorcfm+ 
ILCs may shape the tumor microenvironment in a way that 
it is more conducive for other immune effector cells to in-
vade. Similar to LTi’s, we found high levels of the chemo-
kine receptors CCR2, CCR6, CCR7, CCR8, and CXCR5 
in splenic Rorcfm+ ILCs, compared with siLP Rorcfm+ ILCs 
(Fig. 7 A), suggesting an involvement of ILCs in the forma-
tion of lymphoid structures (Shields et al., 2010). Along that 
line, splenic Rorcfm+ ILCs showed an activated phenotype, 
indicated by greater expression levels of MHC II, CD74, and 
CD28 compared with siLP Rorcfm+ ILCs (Fig. S5 B). To fur-
ther analyze the tumor microenvironment and the pattern 
of tumor-infiltrating immune cells, we coinjected B16–IL-12 
tumor cells with splenic and siLP Rorcfm+ ILCs 10 d after 
tumor inoculation by high-dimensional, 22-parameter flow 
cytometry. Unbiased, algorithm-driven analysis revealed dif-
ferences in the tumor-infiltrating immune compartments of 
splenic Rorcfm+ ILCs compared with the other experimental 
groups (Fig. 7, B and C), characterized by increased invasion 
by CD8+ T cells, NK cells, and NKT cells, as well as by acti-
vated myeloid cells (Fig. 7 D). Interestingly, all these cell types 
have previously been shown to be involved in tumor suppres-
sion driven by IL-12 (Kerkar et al., 2011; Tugues et al., 2015) 
and might cooperate to provide an efficient IL-12–driven 
antitumor response through Rorcfm+ ILCs. Taken together, our 
results suggest a preferential recruitment of lymphoid-tissue–
derived Rorcfm+ ILCs to the tumor site, which, in turn, may 
render the tumor microenvironment more conducive to the 
invasion of further immune effectors.
dIscussIon
Since the discovery of LTi’s two decades ago, ILCs have been 
studied intensively and shown to be involved in tissue homeo-
stasis and host defense (Artis and Spits, 2015; Eberl et al., 2015; 
Sonnenberg and Artis, 2015). It is becoming increasingly clear 
that ILCs affect tumor immune surveillance (Eisenring et al., 
2010; Ikutani et al., 2012; Kirchberger et al., 2013; Chan et al., 
2014; Jovanovic et al., 2014; Li et al., 2014; Crome et al., 2017; 
Irshad et al., 2017). The function of ILCs varies depending 
on the tumor model and tissue localization, raising questions 
as to how the tissue microenvironment influences these cells 
and especially their function. Here, we show that ILC3s adapt 
to their local tissue microenvironment and demonstrate vastly 
different phenotypic characteristics (i.e., marker expression). 
Their functional properties (i.e., tumor suppression), however, 
are guided by their ontogeny (i.e., early transcriptional im-
printing) as well as by adaptation to their tissue microenvi-
ronment, uncoupled from their phenotype.
Although the development of ILC3s has been elucidated 
in various studies (Satoh-Takayama et al., 2010; Cherrier et 
al., 2012; Constantinides et al., 2014; Klose et al., 2014; Mon-
taldo et al., 2014), the effect of the tissue microenvironment 
on their phenotype and function remains largely elusive. No-
tably, our computer-aided dimensionality reduction and clus-
tering showed a clearly demarcated specification for ILC3s in 
lymphoid and nonlymphoid organs. Parabiosis experiments 
demonstrated that ILCs are tissue-resident cells (Gasteiger et 
al., 2015); only a few of them have been found in the circu-
lation, suggesting distinct phenotypes and functions for these 
cells in different tissues. Moreover, the expression of homing 
markers, such as α4β7, CXCR6, CCR9, and CCR7 (Hoyler 
et al., 2012; Chea et al., 2015; Kim et al., 2015; Mackley et 
al., 2015), in ILCs and ILC precursors indicates a differential 
recruitment into tissues or lesions. We found ILC3s to distrib-
ute among various organs in the steady state and to pheno-
typically adapt to their new tissue environment, regardless of 
their origin. Hence, the phenotypic properties of ILC3s are 
not invariably imprinted during early development but are 
acquired upon homing to new localizations. In line with our 
findings, two previous studies demonstrated that a consider-
able part of intestinal Rorcfm+ ILCs lose RORγt expression 
when homing to colon lamina propria or spleen (Vonarbourg 
et al., 2010) and that the transcription factor was reexpressed 
when “inflammatory” ILC1s reconverted to “homeostatic” 
IL-22–producing ILC3s in the small intestine after adop-
tively transferring into Rag2−/−IL2Rg−/− mice (Bernink et 
al., 2015). Taken together, these findings suggest that the tissue 
microenvironment in the steady state provides strong guid-
ance cues for the phenotypic adaptation of ILC3s to an indi-
vidual tissue. Although this hints toward the high plasticity of 
ILCs, single cell-tracing experiments would be necessary to 
fully exclude heterogeneity of the transferred ILC population, 
as well as a differential maturation status or the presence of 
potential precursor cells that might undergo tissue-specific 
maturation or differentiation.
How the splenic and siLP microenvironments drive 
Rorcfm+ cells to predominantly ILC1/NK cells or ILC3 
phenotypes remains unclear. This dichotomy might be ex-
(D) Il12rb2−/− mice were s.c. challenged with B16–IL-12 coinjected with splenic (spl) Rorcfm+ ILCs (open circles), Eomes− ILC1s (open squares), Eomes+ NK 
cells (closed squares), or in the absence of ILCs (closed circles), and tumor growth was measured over time. Graphs represent pooled data from two inde-
pendent experiments, n ≥ 5 each (means ± SEM). For comparison of the tumor growth curve, two-way ANO VA with Tukey’s multiple comparisons test was 
used. ***, P < 0.001. (E) Quantification of tumor burden 21 d after tumor inoculation. Graphs represent pooled data from two independent experiments, n 
≥ 5 each (means ± SEM). One-way ANO VA with Tukey’s multiple comparisons test was performed. *, P < 0.05; **, P < 0.01. (F) PCA of different ILC subsets, 
including splenic NK cells, ILC1s, and Rorcfm+ ILC3s as well as siLP Rorcfm+ ILC3s. (G) Heat map of differentially expressed genes of splenic NK cells, ILC1s 
and (Rorcfm+) ILC3s as well as siLP (Rorcfm+) ILC3s. (H) Heat maps of differentially expressed genes clustered to the indicated category. Heat maps show 
representative data of one sample per group.
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Figure 7. splenic rorcfm+ ILcs render the tumor microenvironment more conducive to immune cell invasion. (A) Chemokine receptor expression 
by the different splenic and siLP Rorcfm+ ILCs; data from NGS (means ± SD; Fig. 6). One-way ANO VA with Tukey’s multiple comparisons test was performed. 
**, P < 0.01; ***, P < 0.001. (B) Dimensionality reduction using t-SNE. Data from tumor-infiltrating immune cells of B16–IL-12 tumors (day 10) coinjected 
with siLP, splenic (spl) Rorcfm+ ILCs, or without ILCs (gated on live, single CD45+) were transformed and plotted in two t-SNE dimensions using R software. 
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plained by the differential functions between both organs—
the lymphoid organs representing a “sterile” environment 
and a site of antigen presentation, whereas the intestine is a 
barrier tissue highly colonized by commensal bacteria. Cy-
tokines, such as IL-23 and IL-1β or IL-12, for example, have 
been shown to induce the ILC3 and the ILC1 phenotypes, 
respectively (Vonarbourg et al., 2010; Bernink et al., 2015). 
Accordingly, we and others found that splenic Rorcfm+ ILCs 
expressed higher levels of the IL-12–specific receptor subunit 
Il12rβ2 compared with siLP Rorcfm+ ILCs, whereas the latter 
population expresses the IL-23 receptor and higher amounts 
of IL-1β receptor. Moreover, mice deficient for IL12a were 
found to have increased numbers of RORγt+NCR− ILC3s 
(Vonarbourg et al., 2010).
In addition to cytokines, commensal bacteria, metabolic 
products, and the dominating cell types populating the differ-
ent tissues may regulate the phenotypic properties of ILC3s. 
For example, the gut metabolite retinoic acid was found to 
induce the conversion of CD127+ ILC1 to IL-22–produc-
ing ILC3 (Bernink et al., 2015). CX3CR1+ mononuclear 
phagocytes/intestinal DCs that develop in the intestine after 
commensal colonization drive the production of IL-22 by 
RORγt+ ILCs (Niess and Adler, 2010; Manta et al., 2013; 
Satoh-Takayama et al., 2014). Further, commensal bacteria 
might be able to stimulate ILCs directly by engaging NCRs, 
such as NKp46 or NKp44, in human or mouse, respectively 
(Esin et al., 2008; Chaushu et al., 2012; Glatzer et al., 2013).
Rorcfm+ ILCs, more precisely LTi’s, are implicated in 
the organogenesis of lymphoid structures, thus having a 
constructive or organizational character. In addition, they 
may interfere with the establishment of the tumor tissue it-
self or tumor-associated lymphoid structures. High lympho-
cyte infiltration (recruited by chemokines such as CCL21) 
and a tumor landscape resembling lymphoid structures have 
been suggested to be beneficial for tumor suppression (Mes-
sina et al., 2012). Early after B16 inoculation, IL-12 led to 
the up-regulation of chemokines (such as CCL2, CCL3, 
CCL4, CCL5, CXCR9, and CXCR10; unpublished data) 
that are also associated with LN-like structures in human 
melanoma, pointing toward successful tumor suppression. 
Of those, CCL2 and CCL5, expressed in the tumor mi-
croenvironment, were previously shown to correlate with 
lymphocyte infiltration and tumor destruction (Balkwill, 
2004). Whether IL-12–responsive ILC3s also induce lym-
phoid-like structures in our tumor setting will require fur-
ther investigation, but the presence of NCR+ ILC3s has 
been correlated with increased lymphoid structures and 
beneficial clinical outcome in patients with human lung 
cancers (Carrega et al., 2015), suggesting that Rorcfm+ ILCs 
have a role at the tumor–immune interphase in preclinical 
models and patients alike.
We show that the tumor-suppressive properties of 
Rorcfm+ ILCs are shaped not only during their lineage com-
mitment but also by the tissue microenvironment. As such, 
lymphoid tissue–derived Rorcfm+ ILCs are sensitive to IL-12 
and suppress tumor growth, whereas intestinal Rorcfm+ ILCs 
fail to do so. In contrast, ILCs that mainly reside in mucosal 
barrier tissues engage the IL-23/IL-17 axis to protect against 
invading pathogens and have been reported to drive gut tu-
morigenesis (Chan et al., 2014). Collectively, these studies 
demonstrate how powerful the tissue microenvironment ef-
fects on Rorcfm+ ILCs are and how it shapes them along the 
IL-12/IL-23 axis toward a pro- or antitumorigenic response 
(Eisenring et al., 2010; Chan et al., 2014).
Even though the cellular tissue origin of tumor- 
suppressive ILCs remains unknown, our data suggest that they 
might arise from the lymphatic system, where they promptly 
react to and/or initiate a type 1 immune response. A recent 
study showed active migration of ILCs in response to CCR7 
and CCR9 (Mackley et al., 2015), indicating that ILCs ac-
tively migrate to certain tissues upon triggering of homing 
receptors. In our setting of IL-12–mediated tumor suppres-
sion, Rorcfm+ ILCs are recruited to the tumor tissue, in all 
likelihood, responding to specific chemokines present in the 
activated tumor tissue. Once Rorcfm+ ILCs are present in 
the tumor, they render the tumor microenvironment more 
conducive to the invasion of immune effectors, potentially 
activating the adaptive immune system and/or, as previously 
hypothesized, by potentiating the crosstalk between innate 
and adaptive antitumor immune responses.
The effect of IL-12–induced plasticity and the tissue 
microenvironment on the phenotype and function of ILCs 
seems undisputable (Cella et al., 2010; Vonarbourg et al., 2010; 
Klose et al., 2013, 2014; Huang et al., 2014; Bernink et al., 
2015; Bal et al., 2016; Lim et al., 2016; Ohne et al., 2016) 
and justifies further analysis of the mechanism by which ILCs 
can alter the tumor microenvironment. Moreover, we show a 
convergence of ontogeny, phenotype, and function, suggest-
ing that classification of ILC subsets based on their pheno-
typic properties seems unreliable because ILCs are guided 
primarily by their ontogeny (i.e., transcriptional regulation) 
and the tissue they reside in.
MAterIALs And MetHods
study design
Our aim was to study the effect of the tissue microenvi-
ronment and ontogeny on the phenotype and function of 
ILC3s by investigating their tumor-suppressive capacity. We 
Clustering was performed using the flowSOM algorithm (k = 8). Depicted are an annotated, combined data set (top) and the data sets of tumor-infiltrating 
immune cells of tumors coinjected with siLP Rorcfm+ ILCs (left), splenic Rorcfm+ ILCs (middle), and without ILCs (right). (C) Lymphocyte and myeloid-associated 
markers plotted in a heat map across flowSOM clusters from B. (D) Quantification of the altered cell populations identified in B using manual gating. Graphs 
represent pooled data from two independent experiments, n ≥ 5 each (means ± SEM). *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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used several genetically modified mouse models for tumor 
experiments and to distinguish various ILC3 and ILC1 sub-
sets. Age- and sex-matched mice were randomly divided into 
experimental groups. Experiments to characterize the phe-
notype and determine the function of ILC3s were performed 
at least two times with three to eight mice per group. All 
animal care and handling were performed according to the 
guidelines by the Swiss cantonal veterinary office.
Mice
Mice were housed in individually ventilated cages under 
specific pathogen-free conditions. Conventional C57BL/6 
mice (WT) were purchased from Janvier Labs. Il12rb2−/−, 
Rag1−/−, Rag2−/−Il2rg−/−, and RorcGFP/+ (Rorc−/−) mice 
were purchased from The Jackson Laboratory. Il15ra−/− mice 
were provided by S. Bulfone-Paus (Forschungszentrum Bor-
stel, Borstel, Germany); Rorc-eYFP and Rorccre mice by A. 
Diefenbach (University of Mainz, Mainz, Germany); and 
EomesGFP/+ mice by S.J. Arnold (University of Freiburg, 
Freiburg, Germany;  Arnold et al., 2009). All experimental 
procedures were performed according to the animal licenses 
approved by the Swiss cantonal veterinary office (licenses 
145/2012 and 142/2015).
tumor cell lines
B16.F10 melanoma cells were purchased from ATCC. The 
generation of tumor cell lines stably producing IL-12:Fc or 
Fc has been previously described (Eisenring et al., 2010). B16 
tumor cells were cultured in DMEM (PAN-Biotech) supple-
mented with 10% FBS (Biochrom), 1% glutamine (Gibco), 
1% sodium-pyruvate (Gibco), and 1% penicillin-streptomy-
cin (Invitrogen; hereafter, referred to as complete medium). 
Transfected cell lines were selected with hygromycin B 
(Invitrogen) and maintained at 37°C, 5% CO2.
tumor transplantation and monitoring
A total of 2 × 105 tumor cells were s.c. injected into the lateral 
abdomen of the mouse. Tumor growth was measured three 
times a week. Animals that showed clinical symptoms, such 
as apathy, severe hunchback posture, weight loss of >20% of 
peak weight, and/or tumor ulceration were euthanized.
IL-12 treatment
IL-12:Fc (IL-12) was administered systemically i.p. or local 
intratumoral, at a dose of 200 µg three times a week. Pro-
duction and purification of mouse IL-12:Fc (IL-12) was per-
formed as previously described (vom Berg et al., 2013).
Lymphocyte isolation
Mice were sacrificed by CO2 inhalation, perfused with 25 ml 
ice-cold PBS, and organs were harvested and processed as 
follows. Lymphoid organs were digested in 0.4 mg/ml col-
lagenase IV (from Clostridium histolyticum; Sigma-Aldrich) 
in HBSS, including MgCl2 and CaCl2 (Gibco) supplemented 
with 10% FBS for 30 min at 37°C and agitated. The lung 
and the liver tissues were digested using 1 mg/ml collagenase 
IV. For liver samples, a Percoll gradient was performed (con-
tinuous gradient, 27%; GE Healthcare). The colon and small 
intestine were digested as described before (Burkhard et al., 
2014). The skin and tumor tissue were isolated using 1 mg/ml 
collagenase IV and 0.2 mg/ml DNase I (Sigma-Aldrich) for 
1 h at 37°C and agitating.
Flow cytometry and cell sorting
Single-cell suspensions were stained for 20–30 min at 4°C 
in PBS. Fluorochrome-conjungated antibodies specific 
against mouse c-KIT (2B8), CCR6 (29-2L17), CD103 (2E7), 
CD11c (N418, HL3), CD19 (6D5, 1D3), CD27 (LG.3A10), 
CD3 (145-2C44), CD4 (GK1.5, RM4-5), CD45 (30-F11), 
CD49b (DX5), CD5 (53–7.3), Eomes (Dan11mag), GM-CSF 
(MP1-22E9), IFN-γ (XMG1.2), IL-17 (TC11-18H10), IL-
7Rα (A7R34, SB/199), NK1.1 (PK136), NKp46 (29A1.4), 
RORγt (Q31-378), Sca-1 (D7), T-bet (4B10), TCRβ (H57-
597), and Thy1.2 (30-H12, OX-7) were purchased from Bio-
Legend, BD, or eBioscience. In all staining, dead cells were 
excluded using Live/Dead fixable staining reagents (Invitro-
gen), and doublets were excluded by FSC-A versus FSC-H 
and SSC-A versus SSC-H gating. Samples were acquired 
using a FAC SCanto II, LSR Fortessa II, or FACSymphony 
flow cytometer and FAC SDiva software (BD). Cell sorting 
was performed on a FAC SAria III (BD) using a 70-µm noz-
zle, with a purity of >95%. Data analysis was performed using 
FlowJo 10.0.8 software (Tree Star). For some graphs, data 
from several individual samples were concatenated in FlowJo.
In vitro stimulation and intracellular staining
For cytokine staining, cells were stimulated for 4 h at 37°C in 
complete RPMI with 0.05 µg/ml PMA, 0.5 µg/ml ionomycin, 
and 1 µl/ml brefeldin A (GolgiPlug; Invitrogen). Intracellular 
staining was performed using the Cytofix/Cytoperm kit (BD) 
or the Foxp3/transcription factor staining buffer set (eBiosci-
ence), according to manufacturer’s instructions with the re-
spective antibodies at 4°C for 30–60 min or overnight.
Automated population identification in high-dimensional 
data analysis and t-sne dimensionality reduction
After preprocessing of the flow cytometric data gating on 
live, single CD45+Rorcfm+(YFP+) ILCs, flow cytometry 
standard (.fcs) files of splenic and siLP Rorcfm+ ILCs were 
down-sampled to 4 × 104 events per sample and combined 
into one file. FlowSOM clustering algorithm was used to 
identify biologically meaningful clusters in an unbiased way 
using R software, and the created nodes were subjected to 
meta-clustering. The flowSOM algorithm clusters cells with 
similar phenotypic appearance into subpopulations or sub-
sets, which are depicted in special proximity on the t-SNE 
plot (Levine et al., 2015; Van Gassen et al., 2015). To identify 
meaningful ILC subsets, based on knowledge of the litera-
ture, a k-value of 5 was chosen. Heat maps were drawn using 
the ggplot2 R package to display median expression levels 
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for the indicated clusters. Dendrograms were calculated using 
hierarchical clustering. To visualize the high-dimensional 
data and clusters, two-dimensional t-SNE plots were created 
using R software and were overlayed with the clusters created 
by the FlowSOM algorithm.
rnA isolation and quantitative rt-Pcr
RNA isolation was conducted using the RNeasy Mini Plus 
or Micro Plus Kits (QIA GEN). First-strand cDNA synthesis 
was performed using Superscript II reverse transcription (In-
vitrogen) and oligo (dT) priming (PeproTech), according to 
the manufacturers’ protocols.
Quantitative analysis was conducted using a SYBR 
Green master mix (Roche). The PCR reaction was performed 
with a C1000 Touch thermal cycler (Bio-Rad Laboratories). 
For analysis, cycle threshold values of the genes of interest 
were normalized to the values of the polymerase 2 (Pol2) 
gene (as housekeeping gene). Primers used were IL12rb2 
(forward): 5′-TGT GGG GTG GAG ATC TCA GT-3′; IL12rb2 
(reverse): 5′-TCT CCT TCC TGG ACA CAT GA-3′; IL-23r 
(forward): 5′-CCA AGT ATA TTG TGC ATG TGA AGA-3′; 
IL-23r (reverse): 5′-AGC TTG AGG CAA GAT ATT GTT GT-
3′; Pol2 (forward): 5′-CTG GTC CTT CGA ATC CGC ATC-
3′; Pol2 (reverse): 5′-GCT CGA TAC CCT GCA GGG TCA-3′.
nGs
For NGS, tumor tissue was resected 5 d after tumor 
inoculation and was immediately transferred into RNAlater 
stabilization solution (Ambion). For total RNA isolation, the 
tumor tissue was homogenized using a tissue homogenizer 
(Omni International), and total RNA was extracted using 
the RNeasy Micro Kit Plus (QIA GEN) according to the 
manufacturer’s instructions. NGS was performed by the 
Functional Genomic Center Zurich (http ://www .fgcz 
.ch) using the HiSeq 2500 v4 System (Illumina). Quality 
control included the fastqc and DESeq2 analysis. The GO 
pathway analysis of tumor tissues was performed using the 
MetaCore software (Thomson Reuters), and visualization was 
performed with the TM4 MultiExperiment Viewer (Saeed et 
al., 2003). Pathway analysis of differentially expressed genes in 
splenic Rorcfm+ ILCs versus splenic Eomes− ILC1s, Eomes+ 
NK cells and siLP Rorcfm+ ILCs (based on Fig. S3) using 
David Bioinformatics Resources to extract GO terms “BP” 
(biological process) and “ReViGo” for visualization of the 
false discovery rate: Benjamini-Hochberg ≤ 0.01. PCA was 
performed using Matlab 2014b (MathWorks).
statistical analysis
To analyze data statistically, GraphPad Prism 6.0 software 
(GraphPad Software) was used. A two-tailed unpaired t test 
was performed to determine statistical significance between 
two groups. Welsh's correction was applied in case of signifi-
cantly different variances. For three or more groups, one-way 
ANO VA with Tukey's multiple comparisons test was per-
formed. For comparison of the tumor growth curve two-way 
ANO VA with Tukey’s multiple comparisons test was used; 
p-values <0.05 were considered significantly different (exact 
p-values indicated in figure legends). Data are displayed as 
means ± SEM, unless otherwise stated.
online supplemental material
Fig. S1 shows that Rorcfm+ ILCs from various organs pos-
sess different expression patterns. Fig. S2 shows that lymphoid 
Rorcfm+ ILCs suppress tumor growth, whereas nonlymphoid 
Rorcfm+ ILCs fail to do so. Fig. S3 shows a schematic repre-
sentation of Rorc fate map crossed to Eomes reporter mice, 
which allows identification of type 1 and type 3 ILC subsets 
(gating strategy). Fig. S4 NGS reveals differentially expressed 
genes by splenic Rorcfm+ ILCs compared with other ILC 
subsets. Fig. S5 shows splenic Rorcfm+ ILCs only express low 
amounts of cytotoxic molecules and an activated phenotype.
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